The U.K. pharmacovigilance market size is expected to reach USD 510.37 million by 2028, according to a new report by the publisher It is expected to expand at a CAGR of 11.9% from 2021 to 2028. The increasing outsourcing and externalization of clinical trials by the majority of the pharmaceutical and biotechnological companies, regulatory mandates on clinical trial conduct, and post-marketing vigilance are likely to drive the market at an unprecedented rate throughout the forecast period.
Moreover, the introduction of technologically advanced and user-friendly software systems, such as cloud-based PV platforms, is anticipated to drive the market in the coming years. In June 2017, Genpact launched Pharmacovigilance Artificial Intelligence (“PVAI”) solution to alter drug safety data management and reporting. While in December 2020, the Medicines and Healthcare products Regulatory Authority (MHRA) signed a deal with Genpact for obtaining the PVAI tool for USD 2.07 million. In that way, the U.K. became one of the world’s first drug regulators to usage an AI tool to record and process adverse drug reactions.
Throughout the past decade, the augmented usage of numerous expedited review approaches and other developments have led to a decline in the time taken to bring new drugs to the market. While this hastening has led to more quick access for patients, it also upsurges the risk of adverse drug reactions being spotted for the first time when the product is already in the market, leading to the higher demand for post-approval safety surveillance studies and related actions. This is eventually supporting the overall market growth.
Although COVID-19 is forcing many medical device and drug developers to revise their approach to handle the crisis, integrating best practices within clinical trial procedures and adoption of virtual trials can support the constant progress of therapeutics in the pandemic environment. For instance, PPD deployed remote site-monitoring tools to replace on-site visits for COVID-19safety, enabling trial continuation. An increase in R&D and the adoption of new technologies in clinical research are likely to further drive the market. For instance, in April 2020, IBM launched AI-based technologies and COVID-19 high-performance computing consortium to assist research and health communities and accelerate the discovery of medical insights and treatments for COVID-19.
The rising number of contract research organizations and increased demand for outsourcing services are expected to fuel the market competition among market players in the near future. Key participants are involved in continuous product development, partnerships, mergers, and acquisitions to augment market penetration. For instance, in march 2021, ProPharma Group acquired Diamond Pharma Services. This acquisition will help in solidifying ProPharma Group's position as the leading global provider of regulatory, compliance, pharmacovigilance, and medical information services.
This product will be delivered within 1-3 business days.
Moreover, the introduction of technologically advanced and user-friendly software systems, such as cloud-based PV platforms, is anticipated to drive the market in the coming years. In June 2017, Genpact launched Pharmacovigilance Artificial Intelligence (“PVAI”) solution to alter drug safety data management and reporting. While in December 2020, the Medicines and Healthcare products Regulatory Authority (MHRA) signed a deal with Genpact for obtaining the PVAI tool for USD 2.07 million. In that way, the U.K. became one of the world’s first drug regulators to usage an AI tool to record and process adverse drug reactions.
Throughout the past decade, the augmented usage of numerous expedited review approaches and other developments have led to a decline in the time taken to bring new drugs to the market. While this hastening has led to more quick access for patients, it also upsurges the risk of adverse drug reactions being spotted for the first time when the product is already in the market, leading to the higher demand for post-approval safety surveillance studies and related actions. This is eventually supporting the overall market growth.
Although COVID-19 is forcing many medical device and drug developers to revise their approach to handle the crisis, integrating best practices within clinical trial procedures and adoption of virtual trials can support the constant progress of therapeutics in the pandemic environment. For instance, PPD deployed remote site-monitoring tools to replace on-site visits for COVID-19safety, enabling trial continuation. An increase in R&D and the adoption of new technologies in clinical research are likely to further drive the market. For instance, in April 2020, IBM launched AI-based technologies and COVID-19 high-performance computing consortium to assist research and health communities and accelerate the discovery of medical insights and treatments for COVID-19.
The rising number of contract research organizations and increased demand for outsourcing services are expected to fuel the market competition among market players in the near future. Key participants are involved in continuous product development, partnerships, mergers, and acquisitions to augment market penetration. For instance, in march 2021, ProPharma Group acquired Diamond Pharma Services. This acquisition will help in solidifying ProPharma Group's position as the leading global provider of regulatory, compliance, pharmacovigilance, and medical information services.
U.K. Pharmacovigilance Market Report Highlights
- By product life cycle, phase IV dominated the market in 2020 phase IV clinical studies are complex in design and large in scale. Besides, this is an imperative phase of clinical trials as unanticipated adverse drug reactions can be spotted in this phase
- In terms of service provider, contract outsourcing held a dominant share in 2020 owing to the rapidly emerging CROs providing end-to-end clinical trial solutions and outsourcing trends in the pharmaceutical, biotechnology, and medical devices industries. In January 2018, Concept Life Sciences and Alderley Analytical signed a partnership contract to deliver high-value bio analytical and DMPK study services
- Based on type, spontaneous reporting held the largest share of over 30.0% in 2020 owing to its wide usage in the detection of new, serious, and rare ADRs and its popularity as an efficient and inexpensive method. Spontaneous reporting during the post marketing phase produces most drug safety data, yet more than clinical trials during drug development, thereby boosting demand
- On the basis of process flow, the case data management segment is expected to witness the fastest growth over the forecast period. The adverse event information can be generated from various modes, such as post-marketing programs, clinical trials, spontaneous reports, and literature. Some of the data management software include PV-Works Human, ClinSource, and Oracle
- The oncology therapeutic area segment held the largest share of over 25.0% in 2020. Monitoring the safety of cancer drugs is very important due to the associated side effects, which is propelling the demand for pharmacovigilance services
- The biotechnology companies end-use segment is anticipated to exhibit the highest CAGR of 12.6% over the forecast period. The number of U.K. biotechnology corporations has boomed, growing by 65% since 2016
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1 Research Methodology & Scope1.1 Market Segmentation & Scope
1.1.1 Service Provider
1.1.2 Type
1.1.3 Product Life Cycle
1.1.4 Process Flow
1.1.5 Therapeutic area
1.1.6 End use
1.1.7 Country Scope
1.1.8 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased database:
1.3.2 Internal database
1.3.3 Secondary sources
1.3.4 Primary Research:
1.3.5 Details of Primary Research
1.3.5.1 Data for primary interviews
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.7 List of Secondary Sources
1.8 List of Abbreviations
1.9 Market Definitions
1.10 Report Objectives
1.10.1 Objective 1:
1.10.2 Objective 2:
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 U.K. Pharmacovigilance Market Outlook, 2016 - 2028 (USD Million)
2.3 Segment Outlook
2.4 Competitive Outlook
Chapter 3 Pharmacovigilance Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent market analysis
3.1.2 Ancillary market Analysis
3.2 Penetration & Growth Prospect Mapping
3.3 Pharmacovigilance Market Dynamics
3.3.1 Market driver analysis
3.3.2 Market restraint analysis
3.3.3 Industry Challenges
3.4 U.K. Pharmacovigilance Market Analysis Tools: Porters
3.5 SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
3.6 Value Chain Analysis
3.6.1 Pre-clinical
3.6.2 Clinical
3.6.3 PMA
3.7 Mapping of Life Cycle Against Service Offering and Their Demand
3.8 Regulatory Framework
3.9 Pharmacovigilance: Organization Structure Introduction
3.10 Pricing Models
3.10.1 Drug safety Budget Allocation by Activities
3.10.2 By Development phase
3.10.3 By Therapeutic area
3.10.4 Pricing Level
3.10.4.1 Case processing
3.10.4.2 ADR Reporting
3.10.4.3 Medical writing
3.10.4.4 Drug safety management
3.11 Technology Timeline Overview
3.11.1 Changing Technology & Adoption
3.11.1.1 Social Media
3.11.1.2 Literature screening
3.11.1.3 Automation and AI
3.11.1.4 Big data analytics in PV
Chapter 4 COVID-19 Impact Analysis
4.1 COVID-19 Outbreak
4.1.1 U.K.: COVID-19 Disease Prevalence
4.2 Current and Future Impact Analysis
4.3 Recent Developments & Strategic Outcomes
4.3.1 Regulatory requirements/changes due to Covid-19
4.3.2 Strategies implemented by companies
4.3.2.1 IQVIA
4.3.2.2 PARAXEL International Corporation
4.3.2.3 Bioclinica
4.3.2.4 Pharmaceutical Product Development (PPD)
4.3.2.5 IBM Corporation
4.3.2.6 ICON, plc
4.3.2.7 ArisGlobal
Chapter 5 Pharmacovigilance Market: Service Provider Estimates & Trend Analysis
5.1 Service Provider Market Share Analysis, 2020 & 2028
5.2 Service Provider Dashboard
5.2.1 In-house
5.2.1.1 In-house market estimates and forecasts, 2016 - 2028 (USD Million)
5.2.2 Contract Outsourcing
5.2.2.1 Contract outsourcing market estimates and forecasts, 2016 - 2028 (USD Million)
Chapter 6 Pharmacovigilance Market: Type Estimates & Trend Analysis
6.1 Type Market Share Analysis, 2020 & 2028
6.2 Type Dashboard
6.2.1 Spontaneous Reporting
6.2.1.1 Spontaneous Reporting market estimates and forecasts, 2016 - 2028 (USD Million)
6.2.2 Intensified ADR Reporting
6.2.2.1 Intensified ADR Reporting market estimates and forecasts, 2016 - 2028 (USD Million)
6.2.3 Targeted Spontaneous Reporting
6.2.3.1 Targeted spontaneous reporting market estimates and forecasts, 2016 - 2028 (USD Million)
6.2.4 Cohort Event Monitoring (CEM)
6.2.4.1 CEM market estimates and forecasts, 2016 - 2028 (USD Million)
6.2.5 EHR Mining
6.2.5.1 EHR Mining market estimates and forecasts, 2016 - 2028 (USD Million)
Chapter 7 Pharmacovigilance Market: Product Life Cycle Estimates & Trend Analysis
7.1 Product Life Cycle Market Share Analysis, 2020 & 2028
7.2 Product Dashboard
7.2.1 Pre-clinical
7.2.1.1 Pre-clinical market estimates and forecasts, 2016 - 2028 (USD Million)
7.2.2 Phase I
7.2.2.1 Phase I market estimates and forecasts, 2016 - 2028 (USD Million)
7.2.3 Phase II
7.2.3.1 Phase II market estimates and forecasts, 2016 - 2028 (USD Million)
7.2.4 Phase III
7.2.4.1 Phase III market estimates and forecasts, 2016 - 2028 (USD Million)
7.2.5 Phase IV
7.2.5.1 Phase IV market estimates and forecasts, 2016 - 2028 (USD Million)
Chapter 8 Pharmacovigilance Market: Process Flow Estimates & Trend Analysis
8.1 Process Flow Market Share Analysis, 2020 & 2028
8.2 Process Flow Dashboard
8.2.1 Case data management
8.2.1.1 Case data management market estimates and forecasts, 2016 - 2028 (USD Million)
8.2.1.2 Case logging
8.2.1.3 Case logging market estimates and forecasts, 2016 - 2028 (USD Million)
8.2.1.4 Case data analysis
8.2.1.5 Case data analysis market estimates and forecasts, 2016 - 2028 (USD Million)
8.2.1.6 Medical reviewing and reporting
8.2.1.7 Medical reviewing and reporting market estimates and forecasts, 2016 - 2028 (USD Million)
8.2.2 Signal detection
8.2.2.1 Signal detection market estimates and forecasts, 2016 - 2028 (USD Million)
8.2.2.2 Adverse Event Logging
8.2.2.3 Adverse Event Logging market estimates and forecasts, 2016 - 2028 (USD Million)
8.2.2.4 Adverse Event Analysis
8.2.2.5 Adverse Event Analysis market estimates and forecasts, 2016 - 2028 (USD Million)
8.2.2.6 Adverse Event Review & Reporting
8.2.2.7 Adverse Event Review & Reporting market estimates and forecasts, 2016 - 2028 (USD Million)
8.2.3 Risk Management System
8.2.3.1 Risk Management System market estimates and forecasts, 2016 - 2028 (USD Million)
8.2.3.2 Risk Evaluation System
8.2.3.3 Risk Evaluation System market estimates and forecasts, 2016 - 2028 (USD Million)
8.2.3.4 Risk Mitigation System
8.2.3.5 Risk Mitigation System market estimates and forecasts, 2016 - 2028 (USD Million)
Chapter 9 Pharmacovigilance Market: Therapeutic Area Estimates & Trend Analysis
9.1 Therapeutic Area Market Share Analysis, 2020 & 2028
9.2 Therapeutic Area Dashboard
9.2.1 Oncology
9.2.1.1 Oncology market estimates and forecasts, 2016 - 2028 (USD Million)
9.2.2 Neurology
9.2.2.1 Neurology market estimates and forecasts, 2016 - 2028 (USD Million)
9.2.3 Cardiology
9.2.3.1 Cardiology market estimates and forecasts, 2016 - 2028 (USD Million)
9.2.4 Respiratory systems
9.2.4.1 Respiratory systems market estimates and forecasts, 2016 - 2028 (USD Million)
9.2.5 Others
9.2.5.1 Others market estimates and forecasts, 2016 - 2028 (USD Million)
Chapter 10 Pharmacovigilance Market: End-use Estimates & Trend Analysis
10.1 End-use Market Share Analysis, 2020 & 2028
10.2 End-use Dashboard
10.2.1 Pharmaceuticals
10.2.1.1 Pharmaceuticals market estimates and forecasts, 2016 - 2028 (USD Million)
10.2.2 Biotechnology Companies
10.2.2.1 Biotechnology companies market estimates and forecasts, 2016 - 2028 (USD Million)
10.2.3 Medical Device Manufacturers
10.2.3.1 Medical Device Manufacturers market estimates and forecasts, 2016 - 2028 (USD Million)
10.2.4 Others
10.2.4.1 Others market estimates and forecasts, 2016 - 2028 (USD Million)
Chapter 11 Competitive Outlook
11.1 Market Participation Categorization
11.2 Public Companies
11.2.1 Company market position analysis
11.2.2 Consolidation Trends
11.3 Private Companies
11.3.1 List of key emerging companies
Chapter 12 Company Profiles
12.1 Accenture
12.1.1 Company overview
12.1.2 Service benchmarking
12.1.3 Organization structure & Team Composition
12.1.3.1 Team composition
12.1.4 Financial performance
12.1.5 R&D expenditure
12.1.6 Strategic initiatives
12.1.7 SWOT Analysis
12.2 IQVIA
12.2.1 Company overview
12.2.2 Service benchmarking
12.2.3 Organization structure & Team Composition
12.2.3.1 Team composition
12.2.4 Financial performance
12.2.5 Strategic initiatives
12.2.6 SWOT Analysis
12.33 Cognizant
12.3.1 Company overview
12.3.2 Service benchmarking
12.3.3 Organization structure & Team Composition
12.3.3.1 Team composition
12.3.4 Financial performance
12.3.5 Strategic initiatives
12.3.6 SWOT Analysis
12.4 IBM Corporation
12.4.1 Company overview
12.4.2 Service benchmarking
12.4.3 Organization structure & Team Composition
12.4.3.1 Team composition
12.4.4 Financial performance
12.4.5 R&D expenditure
12.4.6 Strategic initiatives
12.4.7 SWOT Analysis
12.5 ArisGlobal
12.5.1 Company overview
12.5.2 Service benchmarking
12.5.3 Organization structure & Team Composition
12.5.3.1 Team composition
12.5.4 Financial performance
12.5.5 Strategic initiatives
12.5.6 SWOT Analysis
12.6 ICON Plc.
12.6.1 Company overview
12.6.2 Service benchmarking
12.6.3 Organization structure & Team Composition
12.6.3.1 Team composition
12.6.4 Financial performance
12.6.5 Strategic initiatives
12.6.6 SWOT Analysis
12.7 Capgemini
12.7.1 Company overview
12.7.2 Service benchmarking
12.7.3 Organization structure & Team Composition
12.7.3.1 Team composition
12.7.4 Financial performance
12.7.5 Strategic initiatives
12.7.6 SWOT Analysis
12.8 TAKE Solutions
12.8.1 Company overview
12.8.2 Service benchmarking
12.8.3 Organization structure & Team Composition
12.8.3.1 Team composition
12.8.4 Financial performance
12.8.5 Strategic initiatives
12.8.6 SWOT Analysis
12.9 PAREXEL International Corporation
12.9.1 Company overview
12.9.2 Service benchmarking
12.9.3 Organization structure & Team Composition
12.9.3.1 Team composition
12.9.4 Financial performance
12.9.5 Strategic initiatives
12.9.6 SWOT Analysis
12.10 BioClinica, Inc.
12.10.1 Company overview
12.10.2 Service benchmarking
12.10.3 Organization structure & Team Composition
12.10.3.1 Team composition
12.10.4 Financial performance
12.10.5 Strategic initiatives
12.10.6 SWOT Analysis
Chapter 13 Winning Strategies
13.1 Key Winning/Scoring Criteria’s
13.1.1 By categories
13.1.1.1 Pharmaceuticals
13.1.1.2 Biotech companies
13.1.1.3 Medical device companies
13.2 Key Vendor Selection Factors
13.2.1 By Category
13.2.2 BY Company size
13.2.2.1 KEY TAKEAWAYS
13.3 Switching Cost Analysis
13.4 Detailed List of Companies
List of Tables
Table 1 List of secondary sources
Table 2 List of Abbreviation
Table 3 Types of ADRs
Table 4 Adverse Drug Events (ADEs) in hospitals
Table 5 Total literature searches (2013 - 2019)
Table 6 Estimated Total Per-Study Costs (in $ Millions), by Phase and Therapeutic Area
Table 7 Case management costing by year
Table 8 Price by case processing volume
Table 9 Outsourcing trend observed in pharmaceutical companies
Table 10 List of Major Deals & Acquisitions
Table 11 Detailed list of companies in clinical trials in pharmacovigilanceList of Figures
Figure. 1 Market research process
Figure. 2 Data triangulation techniques
Figure. 3 Primary research pattern
Figure. 4 Primary interviews
Figure. 5 Market research approaches
Figure. 6 Value-chain-based sizing & forecasting
Figure. 7 QFD modeling for market share assessment
Figure. 8 Market formulation & validation
Figure. 9 Timeline of pharmacovigilance for a drug from development (premarket to post marketing)
Figure. 10 U.K. Pharmacovigilance Market Estimates and Revenue Forecast, 2016 - 2028 (USD Million)
Figure. 11 U.K. Pharmacovigilance market snapshot, 2020 (USD Million)
Figure. 12 Penetration & growth prospect mapping
Figure. 13 Pharmacovigilance market dynamics
Figure. 14 Pharmacovigilance market driver impact
Figure. 15 Pharmacovigilance market restraint impact
Figure. 16 Porter’s five force model
Figure. 17 Pharmacovigilance - SWOT analysis, by factor (political & legal, economic, and technological)
Figure. 18 Trending topics on social media (2017)
Figure. 19 ADR detection and from social media data
Figure. 20 Common literature automation tool flow
Figure. 21 Automation processes in PV
Figure. 22 Deterrents to Leveraging the Cloud (Oracle Survey)
Figure. 23 The three-step process to compute signal statistics from search log using big data
Figure. 24 Risk Management Capacity &Capability with Pharmacovigilance Using Big Data
Figure. 25 Pharmacovigilance & Patient Safety Services - Product Life Cycle
Figure. 26 PV department
Figure. 27 PV organization structure
Figure. 28 Estimated budget allocation of drug safety activities at global and country-level
Figure. 29 Comparison between estimated global and country-level drug safety budget allocation
Figure. 30 Average % of drug safety budget contributed by function at a global level
Figure. 31 Clinical trial cost by phase (%)
Figure. 32 The average monthly cost of illness due to ADRs
Figure. 33 Covid-19 disease prevalence analysis
Figure. 34 Pharmacovigilance market: Product life cycle movement analysis
Figure. 35 Pharmacovigilance market product life cycle dashboard
Figure. 36 Preclinical market, 2016 - 2028 (USD Million)
Figure. 37 Phase I market, 2016 - 2028 (USD Million)
Figure. 38 Phase II market, 2016 - 2028 (USD Million)
Figure. 39 Phase III market, 2016 - 2028 (USD Million)
Figure. 40 Phase IV market, 2016 - 2028 (USD Million)
Figure. 41 U.K. Pharmacovigilance market: Service provider movement analysis
Figure. 42 Pharmacovigilance Service provider dashboard
Figure. 43 In-house market, 2016 - 2028 (USD Million)
Figure. 44 Contract outsourcing market, 2016 - 2028 (USD Million)
Figure. 45 U.K. Pharmacovigilance market: Type movement analysis
Figure. 46 Pharmacovigilance type dashboard
Figure. 47 Spontaneous reporting market, 2016 - 2028 (USD Million)
Figure. 48 Intensified ADR reporting market, 2016 - 2028 (USD Million)
Figure. 49 Targeted spontaneous reporting market, 2016 - 2028 (USD Million)
Figure. 50 CEM market, 2016 - 2028 (USD Million)
Figure. 51 EHR mining market, 2016 - 2028 (USD Million)
Figure. 52 U.K. Pharmacovigilance market: Process flow movement analysis
Figure. 53 U.K. Pharmacovigilance market process flow dashboard
Figure. 54 Case data management market, 2016 - 2028 (USD Million)
Figure. 55 Case logging market, 2016 - 2028 (USD Million)
Figure. 56 Case data analysis market, 2016 - 2028 (USD Million)
Figure. 57 Medical reviewing and reporting market, 2016 - 2028 (USD Million)
Figure. 58 Signal detection market, 2016- 2028 (USD Million)
Figure. 59 Adverse event logging market, 2016 - 2028 (USD Million)
Figure. 60 Adverse event analysis market, 2016 - 2028 (USD Million)
Figure. 61 adverse event review & reporting market, 2016 - 2028 (USD Million)
Figure. 62 Risk management system market, 2016 - 2028 (USD Million)
Figure. 63 Risk Evaluation System market, 2016 - 2028 (USD Million)
Figure. 64 Risk mitigation system market, 2016 - 2028 (USD Million)
Figure. 65 U.K. Pharmacovigilance market: Therapeutic area movement analysis
Figure. 66 Pharmacovigilance market therapeutic area dashboard
Figure. 67 Oncology market, 2016 - 2028 (USD Million)
Figure. 68 neurology market, 2016 - 2028 (USD Million)
Figure. 69 cardiology market, 2016 - 2028 (USD Million)
Figure. 70 respiratory systems market, 2016 - 2028 (USD Million)
Figure. 71 others market, 2016 - 2028 (USD Million)
Figure. 72 U.K. Pharmacovigilance market: End-use movement analysis
Figure. 73 Pharmacovigilance market end-use dashboard
Figure. 74 Pharmaceuticals market, 2016 - 2028 (USD Million)
Figure. 75 Biotechnology companies’ market, 2016 - 2028 (USD Million)
Figure. 76 Medical device manufacturers market, 2016 - 2028 (USD Million)
Figure. 77 Others market, 2016 - 2028 (USD Million)
Figure. 78 Market participant categorization
Figure. 79 Company market position analysis
Figure. 80 Organization Structure - Accenture
Figure. 81 SWOT - Accenture
Figure. 82 Organization Structure - IQVIA
Figure. 83 SWOT - IQVIA
Figure. 84 Organization Structure - Cognizant
Figure. 85 SWOT - Cognizant
Figure. 86 Organization Structure - IBM
Figure. 87 SWOT - IBM
Figure. 88 Organization Structure - ArisGlobal
Figure. 89 SWOT - ArisGlobal
Figure. 90 Organization Structure - ICON Plc
Figure. 91 SWOT - ICON Plc
Figure. 92 Organization Structure - Capgemini
Figure. 93 SWOT - Capgemini
Figure. 94 Organization Structure - Take Solutions
Figure. 95 SWOT - Take Solutions
Figure. 96 Organization Structure - Paraxel Corporation
Figure. 97 SWOT - PARAXEL
Figure. 98 Organization Structure - BioClinica, Inc.
Figure. 99 SWOT - BioClinica, Inc.
Figure. 100 Commonly outsourced PV activities
Figure. 101 Vendor selection criteria
Companies Mentioned
- Accenture
- IQVIA
- Cognizant
- IBM Corporation
- ArisGlobal
- ICON Plc.
- Capgemini
- TAKE Solutions
- PAREXEL International Corporation
- BioClinica, Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 186 |
| Published | September 2021 |
| Forecast Period | 2020 - 2028 |
| Estimated Market Value ( USD | $ 211.05 Million |
| Forecasted Market Value ( USD | $ 510.37 Million |
| Compound Annual Growth Rate | 11.9% |
| Regions Covered | United Kingdom |
| No. of Companies Mentioned | 10 |
